TBI Modeling Platform
Traumatic Brain Injury
Key Facts
About bmseed
BMSEED is a private, early-stage biotech tools company founded in 2020 and based in San Francisco. It has developed the MEASSuRE platform, which features proprietary stretchable multielectrode arrays (sMEAs) to apply controlled mechanical strain while simultaneously recording and stimulating electrophysiological activity in cell and tissue cultures. This integrated approach addresses a critical limitation in conventional in vitro models by replicating in vivo biomechanics, potentially improving the predictive power of preclinical research in neuroscience, cardiology, and trauma. The company appears to be pre-revenue, focusing on research collaborations and publications to validate its platform for academic and industrial research customers.
View full company profileTherapeutic Areas
Other Traumatic Brain Injury Drugs
| Drug | Company | Phase |
|---|---|---|
| Presendin™ (Exenatide) | Invex Therapeutics | Preclinical |
| TV-301 | TheraVac Biologics | Preclinical |
| TBI Indication | Hera Health Solutions | Proof of Concept/Bench Validation |
| NA-731 | Biomed | Phase 2A |
| Fv-Hsp72 for TBI | Rubicon Biotechnology | Pre-clinical |
| TBI Treatment System | Vivonics | Development/Testing |
| Traumatic Brain Injury (TBI) Implant | Matricelf | Preclinical |